UPDATE: BMO Capital Starts Jasper Therapeutics (JSPR) at Outperform

(Updated - October 20, 2021 4:53 AM EDT)

BMO Capital analyst Matthew Luchini initiates coverage on Jasper Therapeutics (NASDAQ: JSPR) with a Outperform rating and a price target of $19.00.

The analyst comments "We are initiating coverage of JSPR at Outperform and $19 target. Jasper is a clinical stage biotech developing conditioning regimens for hematopoietic stem cell transplant and an engineered stem cell platform. We believe lead product JSP191 has shown encouraging early efficacy and clean safety, a potentially significant advantage that could allow JSP191 to become a backbone or replacement for existing toxic regimens. While shares have been volatile, we are positive on Jasper given early data and longterm potential upside via expansion into autoimmune and gene therapy plus the eHSC platform."

For an analyst ratings summary and ratings history on Jasper Therapeutics click here. For more ratings news on Jasper Therapeutics click here.

Shares of Jasper Therapeutics closed at $13.58 yesterday.

You May Also Be Interested In

• Cantor Fitzgerald Starts Materialise NV (MTLS) at Overweight, 'Well-Positioned to meet rising software demand'
• KeyBanc Starts Super Micro Computer (SMCI) at Sector Weight, 'shares currently trading relatively inline with its infrastructure peer group'
• Enphase Energy (ENPH) PT Raised to $145 at TD Cowen